Stephen Staal

Skip to main content All experts

PRG DIR & CLIN PROF

MD-MEDICINE

PRG DIR & CLIN PROF
MD-MEDICINE

stephen.staal@medicine.ufl.edu (opens in a new tab)

sort by:

GRANT
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma
Bristol Myers Squibb Corporation15 Aug 2022 - 16 May 2025
Closed
GRANT
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma
Bristol Myers Squibb Corporation15 Aug 2022 - 16 Jun 2026
Closed
GRANT
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial assigning individualized Options for Treatment: The TAILORx Trial
Breast Cancer Research Foundation26 Feb 2020 - 26 Jan 2025
Closed
GRANT
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial assigning individualized Options for Treatment: The TAILORx Trial#
Breast Cancer Research Foundation6 Feb 2020 - 15 Dec 2026
Active
GRANT
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma
National Institute of Health Nci1 Mar 2019 - 28 Feb 2026
Expired
GRANT
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
National Institute of Health Nci10 Sep 2015 - 9 Sep 2020
Expired
GRANT
A Randomized Phase II study of MK-3475 versus chemothereapy in Patients with Advanced Melanoma
Merck Sharp & Dohme11 Jul 2013 - 1 May 2016
Expired
GRANT
A RANDOMIZED PHASE II STUDY OF MK-3475 VERSUS CHEMOTHEREAPY IN PATIENTS WITH ADVANCED MELANOMA
Merck Sharp & Dohme2 May 2013 - 20 Nov 2017
Closed
GRANT
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High Dose Interferon a-2b for Resected High Risk Melanoma
National Institute of Health Nci3 Aug 2012 - 1 Apr 2020
Expired
GRANT
A Phase III Clinical Trial comparing the combination of TC plus Bevacizumab to TC alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Genentech Inc27 Jul 2010 - 6 Apr 2019
Expired
GRANT
214 Fund - A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Amgen Inc23 Feb 2010 - 9 Jul 2018
Closed
GRANT
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial assigning individualized Options for Treatment: The TAILORx Trial
National Institute of Health11 Mar 2009 - 1 May 2019
Expired
GRANT
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival i
National Surg Adjuv Breast & Bowel11 Dec 2008 - 21 Aug 2021
Expired

GRANTS